Pain reliever for PsA will get cheaper

| Melissa Leavitt

A popular drug for psoriatic arthritis pain may soon cost a lot less.

For the first time, Celebrex (celecoxib) will become available in generic versions, following approval last week from the Food and Drug Administration (FDA). The FDA approved 50 milligram (mg), 100 mg, 200 mg and 400 mg capsules of the drug.

Celebrex is a nonsteroidal anti-inflammatory drug (NSAID) used to treat rheumatoid arthritis and osteoarthritis. It is sometimes prescribed to help relieve the pain of psoriatic arthritis. Celebrex targets COX-2, which is an enzyme that causes inflammation and pain. Common side effects include stomachache, diarrhea and indigestion.

According to a court decision, the generic will hit the market in December.


Driving discovery, creating community

For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.

Recent Advance Posts

A dermatologist explains the best strategies to itch and crack less this season.
When David Harrold called the Patient Navigation Center, he found answers to...
NPF spoke with Junko Takeshita, M.D., Ph.D., about her research on psoriasis...
Twice-a-day pill slows progression of joint damage in addition to reducing pain...
NPF went face-to-face with the “fail-first” insurance policy that comes between...
Don't settle for a mediocre relationship with your provider. These...
The American College of Rheumatology Annual Meeting spotlights the latest news...
Clinical trial data shows Taltz can improve quality of life for those with PsA.
Howard Chang has battled psoriasis for 35 years. When he heard about Treat to...